Seattle Genetics is reporting positive preliminary results from a phase II trial of its promising anti-cancer drug brentuximab vedotin (SGN-35) against patients with anaplastic large cell lymphoma, (ALCL).
According to the company, 50 of 58 patients with ALCL "responded to treatment" with SGN-35, although they stopped short of breaking down that figure into respose rates, such as complete response and partial response.
Seattle Genetics will present data from this phase II trial in abstract form at the meeting of the American Society of Hematology in Orlando this coming December.
CANCER TYPE(S)
Anaplastic large T-cell lymphoma
TREATMENT TYPE(S)
Biological treatment
Source
BusinessWeek
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
